The following temporary classifications were agreed at a meeting of the WHO International Working Group for Drug Statistics Methodology which took place on 27 and 28 October 1999. Comments on or objections to the classification should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology, P.O. Box 100, Veivet, 0518 Oslo, Norway (telephone: 0047 22 16 96 11, fax: 00 47 22 16 98 18, e-mail: whocc@nmd.no). The new ATC codes and DDDs will be included in the January 2001 issue of the ATC index. The inclusion of a substance in the lists does not imply any recommendation of use in medicine or pharmacy. |
ATC level |
INN/common name |
ATC code |
New ATC level codes (other than 5th level): |
|
Artemisinin and derivatives |
|
P01BE |
|
Nitrofuran derivatives |
|
J01XE |
Change of level name: |
|
Previous: |
|
|
|
Quinine alcaloids |
|
|
|
New: |
|
|
|
Methanolquinolines |
|
P01BC |
|
|
|
New ATC 5th level codes: |
|
ancrod |
B01AD09 |
|
arteether |
P01BE04 |
|
artemether |
P01BE02 |
|
artemether, combinations |
P01BE52 |
|
artemisinin |
P01BE01 |
|
artesunate |
P01BE03 |
|
atosiban |
G02CX01 |
|
bexarotene |
L01XX25 |
|
codeine, combinations with psycholeptics |
N02AA79 |
|
collagenase |
D03BA03 |
|
dermatan sulfate |
B01AX04 |
|
desloratadine |
R06AX27 |
|
dihydroartemisinin |
P01BE05 |
|
dronabinol |
A04AD10 |
|
gentamicin |
S02AA14 |
|
Haemophilus influenzae B and hepatitis B |
J07CA08 |
|
imidapril |
C09AA16 |
|
insulin aspart |
A10AB05 |
|
interferon alfacon-1 |
L03AB09 |
|
levosimendan |
C01CX08 |
|
mitotane |
L01XX23 |
|
mometasone |
D07XC03 |
|
mometasone |
R03BA07 |
|
moxicylyte |
G04BE06 |
|
nabilone |
A04AD11 |
|
omeprazole, amoxicillin and clarithromycin |
A02BD05 |
|
palivizumab |
J06BB16 |
|
pegaspargase |
L01XX24 |
|
peginterferon alfa-2b |
L03AB10 |
|
ribavirin, combinations |
J05AB54 |
|
rofecoxib |
M01AH02 |
|
sorbitol |
A06AD18 |
|
stannous fluoride |
A01AA04 |
|
tasonermin |
L03AX11 |
|
technetium (99m Tc) nanocolloid |
V09EA03 |
|
tositumomab/iodine 131I tositumomab |
V10XA53 |
|
zotepine |
N05AX11 |
ATC code changes: |
|
cinoxacin |
G04AB05 |
J01MB06 |
|
flumequine |
G04AB06 |
J01MB07 |
|
mandelic acid |
G04AG05 |
J01XX06 |
|
mefloquine |
P01BA05 |
P01BC02 |
|
methenamine |
G04AA01 |
J01XX05 |
|
methenamine and sulfonamides |
G04AH01 |
J01RA02 |
|
nalidixic acid |
G04AB01 |
J01MB02 |
|
nifurtoinol |
G04AC02 |
J01XE02 |
|
nitrofurantoin |
G04AC01 |
J01XE01 |
|
nitroxoline |
G04AG06 |
J01XX07 |
|
oxolinic acid |
G04AB04 |
J01MB05 |
|
phenazopyridine and sulfonamides |
G04AH02 |
J01EB20/
J01EC20/
J01ED20* |
|
phenyl salicylate |
G04AD01 |
G04BX12 |
|
pipemidic acid |
G04AB03 |
J01MB04 |
|
piromidic acid |
G04AB02 |
J01MB03 |
ATC codes under revision: |
|
tobramycin |
J01GB01 |
|
thiamphenicol, combinations |
J01BA52 |
* the products should be classified according to the J group on general anti-infectives for systemic use.
New DDDs:
INN/common name |
DDD |
Unit |
Route of Administration |
ATC code |
abacavir |
0.6 |
g |
O |
J05AF06 |
barnidipine |
10 |
mg |
O |
C08CA12 |
cefprozil |
1 |
g |
O |
J01DA41 |
cetrorelix |
0.25 |
mg |
P |
H01CC02 |
chlorphenamine** |
12 |
mg |
P |
R06AB04 |
clopidogrel |
75 |
mg |
O |
B01AC04 |
dicycloverine |
80 |
mg |
O, P |
A03AA07 |
efavirenz |
0.6 |
g |
O |
J05AG03 |
fluticasone |
1.5 |
mg |
inhal. solution |
R03BA05 |
ganirelix |
0.25 |
mg |
P |
H01CC01 |
interferon alfacon-1 |
4 |
mcg |
P |
L03AB09* |
miocamycin |
1.2 |
g |
O |
J01FA11 |
rofecoxib |
12.5 |
mg |
O |
M01AH02* |
rosiglitazone |
6 |
mg |
O |
A10BG02 |
sorbitol |
10 |
g |
O |
A06AD18* |
tasonermin |
3.5 |
mg |
P |
L03AX11* |
* Temporary ATC codes
** previously chlorpheniramine
Change of DDDs:
INN/common name |
DDD |
Unit |
Route of Administration |
ATC code |
cabergoline |
3 |
mg |
O |
N04BC06 |
sumatriptan |
50 |
mg |
O |
N02CC01 |
Chargement en cours...
